Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2012-02-13 (14 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: NOZAY (44170), Loire-Atlantique
PHARMACIE GRANDON : revenue, balance sheet and financial ratios
PHARMACIE GRANDON is a French company
founded 14 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in NOZAY (44170),
this company of category PME
shows in 2024 a revenue of 4.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE GRANDON (SIREN 752288787)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
4 904 841 €
4 780 819 €
4 753 326 €
4 234 861 €
4 071 248 €
3 058 030 €
N/C
N/C
Net income
355 800 €
322 172 €
334 362 €
415 319 €
305 225 €
253 538 €
73 593 €
240 073 €
152 991 €
EBITDA
N/C
452 585 €
503 778 €
640 967 €
492 872 €
422 594 €
304 677 €
N/C
N/C
Net margin
N/C
6.6%
7.0%
8.7%
7.2%
6.2%
2.4%
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE GRANDON generates positive net income of 356 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 153 k€ -> 356 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
355 800 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 53%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 56%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
52.586%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
56.427%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
245.648
175.042
168.53
140.299
129.649
96.822
82.39
63.691
52.586
Financial autonomy
25.788
32.459
33.763
37.324
38.992
44.779
48.242
52.966
56.427
Repayment capacity
None
None
19.32
6.808
5.523
3.83
4.131
4.007
None
Cash flow / Revenue
None%
None%
3.813%
7.685%
8.585%
10.056%
8.121%
7.101%
None%
Sector positioning
Debt ratio
52.592025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average
In 2025, the debt ratio of PHARMACIE GRANDON (52.59) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
56.43%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE GRANDON (56.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
4.01 years2024
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Average
In 2024, the repayment capacity of PHARMACIE GRANDON (4.01) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 211.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
211.352
Liquidity indicators evolution PHARMACIE GRANDON
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
194.028
190.017
229.33
240.093
231.237
244.012
218.854
213.017
211.352
Interest coverage
None
None
54.613
3.665
2.623
1.958
2.336
2.325
None
Sector positioning
Liquidity ratio
211.352025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good
In 2025, the liquidity ratio of PHARMACIE GRANDON (211.35) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
2.33x2024
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Average
In 2024, the interest coverage of PHARMACIE GRANDON (2.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE GRANDON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
458 613 €
379 359 €
377 284 €
533 799 €
384 234 €
390 818 €
0 €
Inventory turnover (days)
0
0
36
27
27
27
26
26
0
Customer payment term (days)
105
110
10
6
8
17
6
6
0
Supplier payment term (days)
819
639
44
39
35
40
37
43
0
Positioning of PHARMACIE GRANDON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE GRANDON is estimated at
5 651 925 €
(range 3 835 423€ - 8 868 649€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
3835k€5651k€8868k€
5 651 925 €Range: 3 835 423€ - 8 868 649€
NAF 5 année 2025
Valuation method used
Net Income Multiple
355 800 €
×
15.9x
=5 651 925 €
Range: 3 835 423€ - 8 868 649€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE GRANDON with other companies in the same sector:
Frequently asked questions about PHARMACIE GRANDON
What is the revenue of PHARMACIE GRANDON ?
The revenue of PHARMACIE GRANDON in 2024 is 4.9 M€.
Is PHARMACIE GRANDON profitable?
Yes, PHARMACIE GRANDON generated a net profit of 356 k€ in 2025.
Where is the headquarters of PHARMACIE GRANDON ?
The headquarters of PHARMACIE GRANDON is located in NOZAY (44170), in the department Loire-Atlantique.
Where to find the tax return of PHARMACIE GRANDON ?
The tax return of PHARMACIE GRANDON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE GRANDON operate?
PHARMACIE GRANDON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart